pubmed-article:20973745 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:20973745 | lifeskim:mentions | umls-concept:C0011847 | lld:lifeskim |
pubmed-article:20973745 | lifeskim:mentions | umls-concept:C0814812 | lld:lifeskim |
pubmed-article:20973745 | lifeskim:mentions | umls-concept:C2348609 | lld:lifeskim |
pubmed-article:20973745 | lifeskim:mentions | umls-concept:C0304522 | lld:lifeskim |
pubmed-article:20973745 | lifeskim:mentions | umls-concept:C1875307 | lld:lifeskim |
pubmed-article:20973745 | pubmed:dateCreated | 2010-12-14 | lld:pubmed |
pubmed-article:20973745 | pubmed:abstractText | Diabetes is a global epidemic. The recommended goals for glycated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and blood pressure are achieved only in a very small minority of patients. In this supplement to Metabolic Syndrome and Related Disorders, we review the data showing that the bile acid sequestrant colesevelam lowers both HbA1c and LDL-C in patients with diabetes. These data make colesevelam an attractive therapy to get more patients to achieve their LDL-C and HbA1c goals. | lld:pubmed |
pubmed-article:20973745 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20973745 | pubmed:language | eng | lld:pubmed |
pubmed-article:20973745 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20973745 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:20973745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20973745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20973745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20973745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20973745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20973745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20973745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20973745 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:20973745 | pubmed:month | Dec | lld:pubmed |
pubmed-article:20973745 | pubmed:issn | 1557-8518 | lld:pubmed |
pubmed-article:20973745 | pubmed:author | pubmed-author:JialalII | lld:pubmed |
pubmed-article:20973745 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:20973745 | pubmed:volume | 8 Suppl 1 | lld:pubmed |
pubmed-article:20973745 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:20973745 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:20973745 | pubmed:pagination | S1-2 | lld:pubmed |
pubmed-article:20973745 | pubmed:dateRevised | 2011-7-20 | lld:pubmed |
pubmed-article:20973745 | pubmed:meshHeading | pubmed-meshheading:20973745... | lld:pubmed |
pubmed-article:20973745 | pubmed:meshHeading | pubmed-meshheading:20973745... | lld:pubmed |
pubmed-article:20973745 | pubmed:meshHeading | pubmed-meshheading:20973745... | lld:pubmed |
pubmed-article:20973745 | pubmed:meshHeading | pubmed-meshheading:20973745... | lld:pubmed |
pubmed-article:20973745 | pubmed:meshHeading | pubmed-meshheading:20973745... | lld:pubmed |
pubmed-article:20973745 | pubmed:meshHeading | pubmed-meshheading:20973745... | lld:pubmed |
pubmed-article:20973745 | pubmed:meshHeading | pubmed-meshheading:20973745... | lld:pubmed |
pubmed-article:20973745 | pubmed:meshHeading | pubmed-meshheading:20973745... | lld:pubmed |
pubmed-article:20973745 | pubmed:year | 2010 | lld:pubmed |
pubmed-article:20973745 | pubmed:articleTitle | Bile acid sequestrants and diabetes: introduction and overview to the supplement. | lld:pubmed |
pubmed-article:20973745 | pubmed:affiliation | Laboratory for Atherosclerosis and Metabolic Research, University of California Davis Medical Center, Sacramento, California, USA. | lld:pubmed |
pubmed-article:20973745 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
pubmed-article:20973745 | pubmed:publicationType | Introductory Journal Article | lld:pubmed |